Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming

July 31, 2018 8:00 AM EDT
Q2 2018 Incyte Corporation Earnings Conference Call

Prior

June 21, 2018 1:00 PM EDT
2018 Investor & Analyst Event

June 13, 2018 12:40 PM CDT
William Blair Growth Conference

June 12, 2018 2:40 PM PDT
Goldman Sachs Global Healthcare Conference

SEC Filings

Filing date Description Filing Group View

Statement of changes in beneficial ownership of securities

3,4,5

Statement of changes in beneficial ownership of securities

3,4,5

Statement of changes in beneficial ownership of securities

3,4,5

Investor Contacts

Michael Booth D.Phil
Vice President, Investor Relations
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Kwiecinski
Director, Investor Relations
Phone: 302.498.6141
E-mail: lkwiecinski@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536